secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001171843-25-004808
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook
--------------------------------------------------------------------------------

- Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).
- AUSTEDO global revs $498M (+19% LC), AJOVY $155M (+31% LC), UZEDY $54M (+120% YoY).
- Raised 2025 revenue outlook: AUSTEDO $2,000-2,050M, AJOVY $630-640M, UZEDY $190-200M.
- Non-GAAP operating margin 27.1% (vs 25.3% Q2 2024); adjusted EBITDA $1,233M (+6%).
- Free cash flow $476M (+47% YoY); on track for $700M net savings by 2027 from Transformation programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/0001171843-25-004808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/f8k_073025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer